Trial Profile
Multicenter, single group study of aripiprazole efficacy and safety in the acute psychosis treatment of schizophrenia, schizophreniform disorder and schizoaffective disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms APLUS
- Sponsors Otsuka Pharmaceutical
- 15 Dec 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2006 New trial record.